2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses high-penetrance genetic syndromes in patients with prostate cancer.
Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses high-penetrance genetic syndromes in patients with prostate cancer.
Many urologists don’t think of prostate cancer as one of the high-penetrance genetic syndromes, especially when compared to kidney cancer, Kane explains.
About 5% to 8% of patients with kidney cancer have a genetic autosomal dominant high-penetrance syndrome. Understanding the recommendation for testing for these syndromes will influence how to tackle the emerging evidence of the genomic and genetic prostate cancer risk, explains Kane.
Related Content: